Up-Regulation of miR-21, miR-25, miR-93, and miR-106b in Gastric Cancer

Larki, Pegah; Ahadi, Alireza; Zare, Ali; Tarighi, Shahriar; Zaheri, Mahrokh; Souri, Mojgan; Zali, Mohammad Reza; Ghaedi, Hamid; Omrani, Mir Davood

doi:10.29252/ibj.22.6.367

Up-Regulation of miR-21, miR-25, miR-93, and miR-106b in Gastric Cancer

Authors

Pegah Larki ¹

Alireza Ahadi ¹

Ali Zare ¹

Shahriar Tarighi ²

Mahrokh Zaheri ³

Mojgan Souri ³

Mohammad Reza Zali ³

Hamid Ghaedi ¹

Mir Davood Omrani ¹

¹ Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

² Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³ Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

10.29252/ibj.22.6.367

Abstract

Background: Differential expression profile of microRNAs (miRNAs) could be a diagnosis signature for monitoring gastric cancer (GC) progression. In this study, we focus on the comparison of expression levels of miR-21, miR-25, miR-93, miR-106b, and miR-375 during the sequential pattern of GC development, including normal gastric, gastric dysplasia, and GC sample. Methods: We used SYBR Green-based quantitative-PCR to quantify miRNAs expression. Results: Our analysis revealed the increased expression levels of miR-21 (p = 0.034), miR-25 (p = 0.0003), miR-93 (p = 0.0406), and miR-106b (p = 0.023) in GC samples. In addition, GC patients with positive lymph node metastasis showed the up-regulation of miR-25, miR-93, and miR-106b (p < 0.05). Conclusion: Our findings suggested that the expression of miR-21, miR-25, miR-93, and miR-106b altered in GC, and some of them may be further investigated as biomarkers for GC early detection and prognosis prediction.

Keywords

Biomarkers

MicroRNAs

Stomach cancer